Why Corxel picked SPAC route to take obesity biotech public
Why Corxel picked SPAC route to take obesity biotech public
Corxel Pharmaceuticals
Private
Cardiometabolic drug developer known as Ji Xing Pharmaceuticals in China, in-licensing and developing cardiovascular and metabolic assets including the oral GLP-1 candidate CX11 for obesity.
Company Info
Sector:Biotechnology — Cardiometabolic
Headquarters:Shanghai, China
Founded:2019
Website:www.corxelbio.com/
Funding Round:Series D ($287 million, 2025)
Total Funding:$287 million Series D plus earlier rounds
Funding & Investor Relations
Notable Investors
- RTW Investments
IPO Outlook / Plans
$377 million SPAC merger announced in 2026 to take the company public